[go: up one dir, main page]

EE200300325A - Asendatud amiini derivaadid ning nende kasutamismeetodid - Google Patents

Asendatud amiini derivaadid ning nende kasutamismeetodid

Info

Publication number
EE200300325A
EE200300325A EEP200300325A EEP200300325A EE200300325A EE 200300325 A EE200300325 A EE 200300325A EE P200300325 A EEP200300325 A EE P200300325A EE P200300325 A EEP200300325 A EE P200300325A EE 200300325 A EE200300325 A EE 200300325A
Authority
EE
Estonia
Prior art keywords
methods
substituted amine
amine derivatives
derivatives
substituted
Prior art date
Application number
EEP200300325A
Other languages
English (en)
Inventor
Chen Guoqing
Adams Jeffrey
E. Bemis Jean
Croghan Michael
Dipietro Lucian
Dominguez Celia
Elbaum Daniel
Germain Julie
Huang Qi
L. Kim Joseph
Ouyang Xiaohu
F. Patel Vinod
M. Smith Leon
Tasker Andrew
Xi Ning
Xu Shimin
Chenguang Yuan Chester
Kim Tae-Seong
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of EE200300325A publication Critical patent/EE200300325A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
EEP200300325A 2001-01-12 2002-01-11 Asendatud amiini derivaadid ning nende kasutamismeetodid EE200300325A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26188201P 2001-01-12 2001-01-12
US32380801P 2001-09-19 2001-09-19
US10/046,622 US7105682B2 (en) 2001-01-12 2002-01-10 Substituted amine derivatives and methods of use
PCT/US2002/003064 WO2002068406A2 (en) 2001-01-12 2002-01-11 Substituted amine derivatives and their use for the treatment of angiogenesis

Publications (1)

Publication Number Publication Date
EE200300325A true EE200300325A (et) 2003-12-15

Family

ID=27366941

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300325A EE200300325A (et) 2001-01-12 2002-01-11 Asendatud amiini derivaadid ning nende kasutamismeetodid

Country Status (16)

Country Link
US (2) US7105682B2 (et)
EP (1) EP1467721A2 (et)
JP (1) JP4338974B2 (et)
KR (1) KR20030078068A (et)
CN (1) CN1538836A (et)
AU (1) AU2002253890B2 (et)
BG (1) BG108013A (et)
CA (1) CA2434178C (et)
CZ (1) CZ20031883A3 (et)
EE (1) EE200300325A (et)
HU (1) HUP0302719A3 (et)
IL (1) IL156737A0 (et)
MX (1) MXPA03006260A (et)
PL (1) PL366834A1 (et)
SK (1) SK8742003A3 (et)
WO (1) WO2002068406A2 (et)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
RU2357957C2 (ru) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
AU2012247083B2 (en) * 2003-03-03 2015-09-24 Array Biopharma, Inc P38 inhibitors and methods of use thereof
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ES2388547T3 (es) * 2003-04-18 2012-10-16 Eli Lilly And Company Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas de 5-HT 1F
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
EP1631560A2 (en) 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
WO2004108133A2 (en) * 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
DK1648998T3 (en) 2003-07-18 2015-01-05 Amgen Inc Specific binding agents for hepatocyte growth factor
BRPI0412259B1 (pt) * 2003-07-22 2019-08-20 Astex Therapeutics Limited Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica
US7390820B2 (en) * 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
MXPA06003164A (es) * 2003-09-23 2006-06-05 Novartis Ag Combinaciones de un inhibidor del receptor de vegf con otros agentes terapeuticos.
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1544213B1 (en) * 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
WO2006008545A2 (en) * 2004-07-22 2006-01-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives as protein kinase inhibitors
US7662837B2 (en) 2004-10-22 2010-02-16 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
ES2611604T3 (es) * 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
CN101084208A (zh) * 2004-10-22 2007-12-05 詹森药业有限公司 作为c－fms激酶抑制剂的芳族酰胺
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2593439C (en) * 2005-01-14 2014-02-25 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
JP5475234B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
AU2006207325B2 (en) * 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
PL1981851T3 (pl) * 2006-01-31 2012-07-31 Array Biopharma Inc Inhibitory kinazy i sposoby ich stosowania
ES2353482T3 (es) 2006-02-10 2011-03-02 Amgen, Inc Formas hidrato de amg706.
RU2470012C2 (ru) 2006-04-11 2012-12-20 Вертекс Фармасьютикалз Инкорпорейтед Композиции, полезные в качестве ингибиторов потенциалзависимых натриевых каналов
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
ES2581600T3 (es) 2006-04-20 2016-09-06 Janssen Pharmaceutica, N.V. Inhibidores de quinasa c-fms
WO2007124319A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
AU2007240437B2 (en) 2006-04-20 2012-12-06 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
GB0612844D0 (en) * 2006-06-28 2006-08-09 Glaxo Group Ltd Compounds
DK2041093T3 (da) * 2006-06-28 2010-08-02 Glaxo Group Ltd Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP2078002B1 (en) * 2006-10-31 2013-08-28 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
TR201900306T4 (tr) * 2006-12-14 2019-02-21 Exelixis Inc Mek inhibitörlerini kullanma yöntemleri.
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
EP2125781A2 (en) 2006-12-20 2009-12-02 Amgen Inc. Substituted heterocycles and methods of use
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
EP3330292A1 (en) 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
JP5555169B2 (ja) * 2007-10-11 2014-07-23 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
NZ584474A (en) 2007-10-11 2012-06-29 Vertex Pharma Amides useful as inhibitors of voltage-gated sodium channels
WO2009049183A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
JP5374377B2 (ja) 2007-10-18 2013-12-25 武田薬品工業株式会社 複素環化合物
ES2445517T3 (es) 2008-08-27 2014-03-03 Leo Pharma A/S Derivados de piridina como inhibidores de receptor VEGFR-2 y proteína tirosina cinasa
BRPI1013763A2 (pt) * 2009-04-16 2015-08-25 Takeda Pharmaceutical Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
EP2675802A1 (en) * 2011-02-14 2013-12-25 Council of Scientific & Industrial Research 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof
DK3363437T3 (da) 2011-02-18 2021-11-01 Endo Pharmaceuticals Inc Aminoindanforbindelser og anvendelse deraf i behandling af smerte
MX2013010871A (es) 2011-03-23 2014-01-31 Amgen Inc Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
CN104370885B (zh) * 2011-03-31 2017-10-10 中国人民解放军军事医学科学院毒物药物研究所 氨基吡啶类衍生物及其用途
CN102718702B (zh) * 2011-03-31 2015-01-07 中国人民解放军军事医学科学院毒物药物研究所 氨基吡啶类衍生物及其用途
WO2012162291A1 (en) * 2011-05-24 2012-11-29 The Wistar Institute Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1
KR101412794B1 (ko) * 2011-07-27 2014-07-01 보령제약 주식회사 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20150057452A1 (en) 2012-04-04 2015-02-26 Catylix, Inc. Selective androgen receptor modulators
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
US9044482B2 (en) 2012-08-15 2015-06-02 Asana Biosciences, Llc Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
CN103012428A (zh) 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CA2899399A1 (en) * 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EP2980088A1 (en) 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EA028614B1 (ru) 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP2977376A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP2977377A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
EP2977375A1 (en) 2014-07-25 2016-01-27 Bayer Pharma Aktiengesellschaft Amino-substituted isoxazoles
ES2887474T3 (es) 2015-01-08 2021-12-22 Univ Leland Stanford Junior Factores y células que proporcionan inducción de hueso, médula ósea y cartílago
SG11201707246YA (en) 2015-03-06 2017-10-30 Pharmakea Inc Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
KR102615565B1 (ko) 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
BR112019004517A2 (pt) 2016-09-07 2019-08-13 Pharmakea, Inc. formas cristalinas de um inibidor lisil-oxidase-semelhante 2 e métodos de preparação
EA201991528A1 (ru) 2016-12-22 2020-01-16 Эмджен Инк. БЕНЗИЗОТИАЗОЛЬНЫЕ, ИЗОТИАЗОЛО[3,4-b]ПИРИДИНОВЫЕ, ХИНАЗОЛИНОВЫЕ, ФТАЛАЗИНОВЫЕ, ПИРИДО[2,3-d]ПИРИДАЗИНОВЫЕ И ПИРИДО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ G12C KRAS ДЛЯ ЛЕЧЕНИЯ РАКА ЛЕГКОГО, РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ ИЛИ КОЛОРЕКТАЛЬНОГО РАКА
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
ES2985118T3 (es) 2017-09-08 2024-11-04 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA52564A (fr) 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
MX2020012731A (es) 2018-06-01 2021-02-22 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
EP4268898A3 (en) 2018-06-11 2024-01-17 Amgen Inc. Kras g12c inhibitors for treating cancer
EP3807276B1 (en) 2018-06-12 2025-12-10 Amgen Inc. Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
MX419368B (es) 2018-12-20 2025-01-14 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a
KR102875569B1 (ko) 2018-12-20 2025-10-23 암젠 인크 Kif18a 억제제
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
US12441736B2 (en) 2018-12-20 2025-10-14 Amgen Inc. KIF18A inhibitors
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
KR20250159270A (ko) 2019-05-21 2025-11-10 암젠 인크 고체 상태 형태
US11427558B1 (en) 2019-07-11 2022-08-30 ESCAPE Bio, Inc. Indazoles and azaindazoles as LRRK2 inhibitors
WO2021026101A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
EP4007752B1 (en) 2019-08-02 2025-09-24 Amgen Inc. Kif18a inhibitors
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
MX2022004656A (es) 2019-10-24 2022-05-25 Amgen Inc Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CN114901366A (zh) 2019-11-04 2022-08-12 锐新医药公司 Ras抑制剂
PH12022550988A1 (en) 2019-11-04 2023-10-09 Revolution Medicines Inc Ras inhibitors
KR20220109408A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
WO2021092115A1 (en) 2019-11-08 2021-05-14 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
AR120457A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
MX2022016355A (es) 2020-06-18 2023-04-03 Revolution Medicines Inc Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
PT4225753T (pt) * 2020-10-08 2024-08-30 Leukos Biotech S L Compostos potentes e seletivos como moduladores do recetor de serotonina 1b
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
TW202304434A (zh) * 2021-04-08 2023-02-01 大陸商杭州阿諾生物醫藥科技有限公司 一種高活性的ｈｐｋ１激酶抑制劑
AR125782A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
AR125787A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN119212994A (zh) 2021-12-17 2024-12-27 建新公司 作为shp2抑制剂的吡唑并吡嗪化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025509217A (ja) 2022-03-07 2025-04-11 アムジエン・インコーポレーテツド ４－メチル－２－プロパン－２－イル－ピリジン－３－カルボニトリルを調製するための方法
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN120504682A (zh) 2022-06-10 2025-08-19 锐新医药公司 大环ras抑制剂
JP2025536257A (ja) 2022-10-14 2025-11-05 ブラック ダイアモンド セラピューティクス，インコーポレイティド イソキノリンまたは６－ａｚａ－キノリン誘導体を使用してがんを治療する方法
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH438343A (de) 1962-11-08 1967-06-30 Thomae Gmbh Dr K Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen
US3226394A (en) 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
US3822277A (en) 1967-11-13 1974-07-02 C Dufour Certain pyridyl cyclopropylamides
BE794226A (fr) 1972-01-21 1973-07-18 Synthelabo Derives de la quinoleine, leur preparation et les medicaments qui en contiennent
ES462495A1 (es) * 1977-09-20 1978-07-16 Antibioticos Sa Procedimiento de preparacion de amidas y esteres.
DE2934543A1 (de) 1979-08-27 1981-04-02 Basf Ag, 6700 Ludwigshafen Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide
DE3305755A1 (de) 1983-02-19 1984-08-23 Gödecke AG, 1000 Berlin N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems
ES2058656T3 (es) 1989-04-20 1994-11-01 Boehringer Ingelheim Pharma 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y su uso en la prevencion o tratamiento del sida.
US5366972A (en) * 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
EP0410148B1 (en) 1989-06-28 1994-04-06 Boehringer Ingelheim Pharmaceuticals Inc. Novel 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and thiones and their use in the prevention or treatment of AIDS
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5571912A (en) 1990-10-19 1996-11-05 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
US5559135A (en) 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5532358A (en) 1994-10-12 1996-07-02 Boehringer Ingelheim Pharmaceuticals, Inc. Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones
TW321649B (et) 1994-11-12 1997-12-01 Zeneca Ltd
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5663357A (en) 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US6008234A (en) 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
NZ337698A (en) 1997-04-04 2001-07-27 Pfizer Prod Inc Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
ES2248911T3 (es) 1997-06-26 2006-03-16 Eli Lilly And Company Agentes antitromboticos.
IL133625A0 (en) 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
AU8270898A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
ES2241151T3 (es) 1997-06-26 2005-10-16 Eli Lilly And Company Agentes antitromboticos.
US6331538B1 (en) * 1997-10-28 2001-12-18 Warner-Lambert Company 7-substituted quinazolin-2,4-diones useful as antibacterial agents
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
IL135536A0 (en) 1997-12-19 2001-05-20 Schering Ag Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
US6506747B1 (en) 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
DE69928260T2 (de) 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE69919212T2 (de) 1998-12-23 2005-07-28 Eli Lilly And Co., Indianapolis Aromatische amiden
ES2196917T3 (es) 1998-12-23 2003-12-16 Lilly Co Eli Amidas heteroaromaticas como inhibidores del factor xa`.
DE69931393T2 (de) 1998-12-23 2007-03-29 Eli Lilly And Co., Indianapolis Antithrombotische amide
MXPA01008182A (es) 1999-02-10 2003-08-20 Astrazeneca Ab Derivados de quinazolina como inhibidores de angiotensina.
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
HN2000000051A (es) 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
AUPQ365299A0 (en) 1999-10-25 1999-11-18 Fujisawa Pharmaceutical Co., Ltd. Anthranilic acid derivatives
US6325123B1 (en) * 1999-12-23 2001-12-04 Dana Corporation Tire inflation system for a steering knuckle wheel end
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
CA2397493A1 (en) 2000-01-27 2001-08-02 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU4890301A (en) 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
DE10023485A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
DE10023492A1 (de) 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10060809A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2002076959A1 (en) 2001-03-23 2002-10-03 Takeda Chemical Industries, Ltd. Five-membered heterocyclic alkanoic acid derivative
US7312235B2 (en) 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US7459470B2 (en) 2001-05-08 2008-12-02 Schering Ag N-oxide anthranylamide derivatives and their use as medicaments
DE50213703D1 (de) 2001-05-08 2009-09-03 Bayer Schering Pharma Ag Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren
GEP20074055B (en) 2002-02-11 2007-03-12 Pfizer Nicotinamide derivatives useful as pde4 inhibitors
GB0203193D0 (en) 2002-02-11 2002-03-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US7517894B2 (en) 2002-07-31 2009-04-14 Bayer Schering Pharma Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines

Also Published As

Publication number Publication date
US20060194848A1 (en) 2006-08-31
SK8742003A3 (en) 2004-03-02
CN1538836A (zh) 2004-10-20
WO2002068406A2 (en) 2002-09-06
CZ20031883A3 (cs) 2004-07-14
US7514564B2 (en) 2009-04-07
PL366834A1 (en) 2005-02-07
US20030195230A1 (en) 2003-10-16
EP1467721A2 (en) 2004-10-20
MXPA03006260A (es) 2003-09-22
KR20030078068A (ko) 2003-10-04
JP4338974B2 (ja) 2009-10-07
WO2002068406A3 (en) 2003-04-24
JP2004527499A (ja) 2004-09-09
CA2434178A1 (en) 2002-09-06
AU2002253890B2 (en) 2005-06-02
IL156737A0 (en) 2004-02-08
CA2434178C (en) 2010-09-21
HUP0302719A3 (en) 2007-08-28
US7105682B2 (en) 2006-09-12
BG108013A (bg) 2004-04-30
HUP0302719A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
EE200300325A (et) Asendatud amiini derivaadid ning nende kasutamismeetodid
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
NO20035634D0 (no) Diamin-derivater
PL377861A1 (pl) Podstawione pochodne aminowe oraz sposoby wykorzystania
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DE60135684D1 (de) Substituierte Bipiperidine -Zwischenverbindungen und deren Derivate
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
ATE341537T1 (de) Dolastatin 10 derivate
DE60233444D1 (de) Teileanbringvorrichtung und teileanbringverfahren
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
EE200400042A (et) 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
DE60208700D1 (de) Schälgerät und zugehörige verfahren
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
DE60336039D1 (de) Verstellbares Bohrgerät und assoziiertes Verfahren
EP1455841A4 (en) COMPOSITIONS AND METHODS RELATED TO OSTEOPONTIN
MA27240A1 (fr) Derives d'imidazoquinoleine
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
ATE456561T1 (de) Anilin-derivate
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
ATE418339T1 (de) Zusammensetzung und verfahren
ATE285408T1 (de) Paroxetin-n-formyl-derivate
DE60226093D1 (de) Urmedium-Reinigungsmethode
ITMO20010226A0 (it) Apparato
DE60238578D1 (de) 3-Acetyl-N-substitutierte-3-aminomethyltetrahydroguran-2-on-Derivate und Verfahren dafür
ZA200305198B (en) Substituted amine derivatives and methods of use.